XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Cancer Channel
subscribe to Cancer newsletter

Latest Research : Cancer

   DISCUSS   |   EMAIL   |   PRINT
Cancer survival improves by combining radiation, chemotherapy & liver transplantation
Sep 10, 2005, 23:04, Reviewed by: Dr.

"We feel that patients with cholangiocarcinoma should have equal access to donor organs, because the results are comparable to those achieved for other patients who undergo transplantation. Without a transplant, the outlook for these patients is fairly poor."

 
A new treatment for patients with a type of bile duct cancer promises a greater chance at survival by combining radiation, chemotherapy and liver transplantation, Mayo Clinic physicians report in the September issue of the Annals of Surgery.

The five-year survival rate for patients who received a liver transplant after radiation and chemotherapy was 82 percent, significantly higher than for those who had a conventional operation. "With the combined benefits of radiation, chemotherapy and liver transplantation, our patients with bile duct cancer now have a much better chance to live longer and enjoy a good quality of life," says Charles Rosen, M.D., a Mayo Clinic transplant surgeon and co-author of the study.

Conventional therapy for hilar cholangiocarcinoma, a type of bile duct cancer, is to remove (resect) the tumor, which may require removing part of the liver. Survival for patients with this type of operation is only 25 to 35 percent, and many patients cannot be treated this way because the tumors can involve both sides of the liver. Combination therapy with liver transplantation is possible for more patients. Transplantation enables surgeons to remove the entire liver and obtain better tumor clearance. Patients treated with transplantation have enjoyed a higher likelihood of prolonged survival than those treated with the conventional operation.

To improve results of liver transplantation for unresectable hilar cholangiocarcinoma, Mayo Clinic physicians developed a treatment protocol combining radiation therapy, chemotherapy and liver transplantation. Patients receive high dose external beam radiation therapy, followed by high dose irradiation with iridium administered through a catheter passing through the bile duct and tumor. Chemotherapy starts during radiation treatment and continues until transplantation. Prior to transplantation, patients undergo a staging abdominal operation so surgeons can look for any spread of the tumor to lymph nodes or the abdomen that would prevent complete tumor removal.

Mayo Clinic's liver transplant team has treated over 90 patients with hilar cholangiocarcinoma. Approximately one-third of the patients have findings at the staging operation that preclude subsequent transplantation, but this number may be decreasing with earlier diagnosis and referral for treatment. Sixty patients have undergone liver transplantation -- many recently with living donors -- and results remain superb, says Dr. Rosen.

Cholangiocarcinoma is a relatively uncommon malignant tumor that is often found in the lining of the bile duct. In the United States, the most common risk factor is sclerosing cholangitis, a chronic liver disease characterized by inflammation, destruction and fibrosis of the bile ducts, often leading to cirrhosis of the liver. The cancer also is seen in patients with congenital bile duct cysts and bile duct stones. Most frequently, these tumors are located near the liver. Cholangiocarcinomas in this location are difficult to treat because the tumor often extends deep into the liver in a way that it cannot be completely removed with a conventional operation.

The incidence of bile duct cancer is increasing in the United States, according to Gregory Gores, M.D., Mayo Clinic liver transplant specialist and co-author of the study. Mayo Clinic has ongoing research into new tests to diagnose the tumor earlier, which could lead to even better results.

"The major problem is that we still don't have enough livers for everyone who needs one," says Dr. Rosen. "We feel that patients with cholangiocarcinoma should have equal access to donor organs, because the results are comparable to those achieved for other patients who undergo transplantation. Without a transplant, the outlook for these patients is fairly poor."
 

- September issue of the Annals of Surgery
 

www.mayoclinic.com

 
Subscribe to Cancer Newsletter
E-mail Address:

 

Other Mayo Clinic physician researchers involved with this study include: David Rea, M.D., Julie Heimbach, M.D., Michael Haddock, M.D., Steven Alberts, M.D., Walter Kremers, Ph.D., and David Nagorney, M.D.

Related Cancer News

Gene Expression Profiling Not Quite Perfected in Predicting Lung Cancer Prognosis
Breast cancer chemotherapy may deterioration in cognitive function
I-ELCAP study: Lung cancer can be detected early with annual low-dose CT screening
Genomic signatures to guide the use of chemotherapeutics
Elderly Breast Cancer Patients May Be Under-Diagnosed And Under-Treated
Listening to the sound of skin cancer
Tissue Geometry Plays Crucial Role in Breast Cell Invasion
Regulatory Approval for New Cotara(R) Brain Cancer Clinical Trial
CDK2/FOXO1 as drug target to Prevent Tumors
Key to lung cancer chemotherapy resistance revealed


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us